Exosomes are increasingly seen as foundational transporters in the human body’s communication machinery and Evox’s technology development is unwaveringly focused on exploiting this natural mechanism for creating a novel form of biotherapeutics. Exosomes can transport various types of biomacromolecules – for instance, protein (REPLACE) and nucleic acid-based (CORRECT) therapeutics – but also various types of small molecule drugs. Crucially, exosomes have also been found to improve the uptake of molecules across natural barriers such as the blood-brain barrier. Evox combines the highly versatile delivery capabilities of exosomes with targeting technology and sophisticated biomolecular engineering approaches. This together with large-scale production methodologies, puts us at the forefront of developing natural delivery capabilities of exosomes for the treatment of severe diseases.
With its roots firmly grounded in two world-renowned academic institutions – Oxford University and the Karolinska Institute – Evox is driven by a dedication to scientific excellence and to pushing the scientific frontier together with an ecosystem of academic partners and collaborators worldwide.